1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
JEIL PHARMA HOLDINGS INC.

JEIL PHARMA HOLDINGS INC.

KKRX:002620
7,200.00
KRW
-20.00
(-0.28%)
1,656.00EPS
11.47P/E
96.71BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
117,978.63
134,625.17
158,233.23
13,637.09
12,896.11
26,520.82
47,672.56
49,661.56
49,707.77
51,658.4
52,399.69
50,804.93
42,821.61
41,096.79
Basic EPS, GAAP
126.44
550.19
2,597.16
2,118.74
139,117
1,362.57
-5,895
745
-227
-4,857
-1,059
-3,333
953
549.44
Free Cash Flow per Basic Share
2,745.98
-2,218.81
-1,146.67
-6,371.73
789.19
-938.65
1,534.53
-2,211.89
-673.56
-2,518.91
-928.82
-151.21
-582
-171.08
Dividend per Share
205.39
135.34
205.62
256.66
238.27
43.04
99.05
103.38
103.65
96.08
73.89
73.87
11.93
- -
Book Value per Share
63,006.92
62,382.93
64,766.47
66,795.03
54,527.67
31,941.23
25,614.28
26,542.15
26,820.87
22,002.6
20,810.28
19,995.26
20,763.34
20,485.35
Tangible Book Value per Share
61,945.29
60,984.6
63,475.1
65,621.68
54,523.32
14,306
14,333.98
15,276.97
16,685.95
16,599.86
17,034.95
19,098.79
19,733.05
19,486.78
Basic Weighted Avg Shares
4
4
4
3
4
5
15
15
15
15
15
15
15
15
Sales/Revenue/Turnover
451,968
512,736
594,716
40,604
48,236
137,609
731,805
761,997
762,568
792,965
804,043
779,822
657,614
630,891
Operating Margin (%)
0.3
1.67
2.21
7.72
9.05
4.23
1.3
2.95
-1.18
-0.95
2.6
-1.43
5.93
2.95
Depreciation Expense
8,370
8,544
8,465
7,680
3,437
1,659
7,396
8,651
8,983
10,905
12,556
14,099
14,949
15,337
Net Income, GAAP
484
2,095
9,761
6,308
520,351
7,070
-90,492
11,431
-3,482
-74,556
-16,250
-51,159
14,635
8,435
Effective Tax Rate (%)
76.91
82.29
39.18
35.64
- -
25.4
- -
51.52
- -
- -
- -
- -
11.99
- -
Profit Margin (%)
0.11
0.41
1.64
15.54
1,078.75
5.14
-12.37
1.5
-0.46
-9.4
-2.02
-6.56
2.23
1.34
Working Capital
108,686
110,678
114,164
119,195
23,156
56,951
-209
7,757
37,120
-5,588
-28,109
31,570
50,213
66,071
LT Debt
8,000
7,000
5,000
27,500
- -
19,906
14,102
12,585
20,108
17,477
11,698
12,667
17,077
22,614
Total Equity
237,602
235,213
241,388
252,080
206,724
589,576
481,848
499,284
500,314
419,792
402,186
437,397
469,117
470,666
Return on Invested Capital (%)
0.12
0.6
3.08
0.7
- -
1.8
- -
1.74
- -
- -
- -
- -
5.56
- -
Return on Capital (%)
0.25
0.88
3.9
1.65
- -
1.67
- -
1.51
- -
- -
- -
- -
0.2
- -
Return on Common Equity (%)
0.2
0.89
4.1
2.57
230.26
2.04
-20.48
2.86
-0.85
-19.89
-4.94
-16.33
4.68
2.7

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
150,292
151,588
162,124
LT Borrowings
16,540
16,480
21,920
LT Finance Leases
537
604
694
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
123,423
129,410
96,712

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
373,283
385,723
394,670
Cash, Cash Equivalents & STI
79,312
83,362
87,505
Accounts Receivable, Net
162,034
164,261
175,309
Inventories
118,839
118,910
116,640
Total Current Liabilities
323,069
317,066
328,599
Payables & Accruals
- -
- -
- -
ST Debt
150,292
151,588
162,124
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.29%
-0.81%
7.25%
Free Cash Flow
-52.52%
68.58%
285.1%
Net Income, GAAP
844.04%
383.7%
-128.61%
Sales/Revenue/Turnover
53.36%
-2.64%
-15.67%
Total Cash Common Dividend
- -
- -
-83.85%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
188,831
197,028
189,997
203,966
779,822
2025
182,043
159,780
161,363
154,427
657,614
2026
150,396
164,704
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3
-799
-143
-2,393.44
-3,333
2025
150
95
232.72
475.91
953
2026
71.83
-231
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
73.87
2025
- -
- -
- -
- -
11.93
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sang-Cheol Han
Full Time Employees
40
Sector
Health technology
Industry
Pharmaceuticals: major
Address
343, Sapyeong-daero Seoul SL South Korea 06543
IPO Date
Jan 20, 1988
Website
jeilph.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Jeil Pharma Holdings Inc. operates as a key player in the South Korean pharmaceutical sector, focusing on the production and distribution of active pharmaceutical ingredients (APIs), specialized incrementally modified drugs, and a broad portfolio of finished dosage forms, including generic medications. The company supplies APIs across diverse medical fields such as oncology, cardiovascular health, gastrointestinal disorders, urology, and antibiotics. Its extensive range of finished products addresses numerous therapeutic categories, including anti-inflammatory conditions, metabolic diseases like hyperlipidemia and diabetes, various neurological and psychiatric issues, and infectious diseases, alongside transdermal patch products and injectable solutions. Jeil Pharma Holdings maintains a strong commitment to research and development, evidenced by its comprehensive R&D centers and advanced manufacturing facilities that adhere to global quality standards such as EU-GMP and US-GMP. Notably, a subsidiary recently received U.S. FDA Orphan Drug Designation for a cancer treatment targeting gastric and gastroesophageal junction cancers, building on a prior designation for pancreatic cancer. The enterprise extends its market reach beyond South Korea, exporting its pharmaceutical offerings to over 40 nations across regions including Southeast Asia, Central and South America, and Africa. Established in 1959, the company's headquarters are located in Seoul, South Korea.